Erdosteine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 15:03, 11 February 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Erdosteine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
oral, inhalation
ATC code
Pharmacokinetic data
Protein binding65%
Metabolismhepatic
Elimination half-life1-3 hours
Identifiers
  • 2-[(2-Oxothiolan-3-yl)carbamoylmethylsulfanyl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.169.984 Edit this at Wikidata
Chemical and physical data
FormulaC8H11NO4S2
Molar mass249.309 g/mol g·mol−1
3D model (JSmol)
  • O=C1SCCC1NC(=O)CSCC(=O)O
  • InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12) checkY
  • Key:QGFORSXNKQLDNO-UHFFFAOYSA-N checkY
  (verify)

Erdosteine is a mucolytic. Specifically it is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine contains two blocked sulfhydryl groups which are released following first-pass metabolism. The three active metabolites exhibit mucolytic and free radical scavenging activity. Erdosteine modulates mucus production and viscosity and increases mucociliary transport, thereby improving expectoration. It also exhibits inhibitory activity against the effects of free radicals produced by cigarette smoke.

Clinical studies in patients with chronic obstructive lung disease have demonstrated the efficacy and tolerability of erdosteine.[1] Erdosteine 300 mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than bromhexine 30 mg twice daily.[citation needed]

Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo.[citation needed]

Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild. The LD50 is very high, 3,500-5,000 mg/kg.

Brand names

Europe:

  • Erdomed
  • Erdopect
  • Erdostin
  • Erdotin
  • Evosten
  • Mucodox
  • Mucofor
  • Theovix
  • Tusselin
  • Vectrine

Other regions:

  • Asdigan
  • Biopulmin
  • Dostein
  • Dostin
  • Dostol
  • Ectrin
  • Edotin
  • Erdos
  • Esteclin
  • Fluidasa
  • Mucoflux
  • Mucotec
  • Mukial
  • Zertin

References

  1. ^ Drugs Exp Clin Res. 2004;30(4):143-52.The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study